 SIOUX FALLS, S.D.--BUSINESS WIRE--- BCYP BARDA--SAB Biotherapeutics SAB, a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that the U.S. Department of Defense DoD has awarded the company an additional 60.5 million in expanded scope for its DiversitAbTM Rapid Response Antibody Program for advanced clinical development through licensure and c 